Rodolfo Batarse, MD
Nephrology · Rancho Mirage, CANPI 1417914193
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $679,534 of the $909,820 with a category attached, or 74.7%. It is spread thinly across 33 manufacturers, the largest accounting for just 16.3%. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,438 payments — averaging $632.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$149K
- Otsuka America Pharmaceutical, Inc.$146K
- Bayer$145K
- Vifor Pharma, Inc.$135K
- Fresenius USA Marketing, Inc.$128K
- Ardelyx, Inc.$64K
- plus $144K from 27 others
Across 2 payments — averaging $1606.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$3K
- Pfizer$713
What the payments were for
- Consulting fees$36,9974%
- Speaking & faculty fees$679,53475%
- Travel & lodging$160,48518%
- Food & beverage$32,3224%
- Education$4830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 214 | $148,726 |
| Otsuka America Pharmaceutical, Inc. | 158 | $145,534 |
| Bayer | 128 | $144,863 |
| Vifor Pharma, Inc. | 249 | $134,866 |
| Fresenius USA Marketing, Inc. | 162 | $128,203 |
| Ardelyx, Inc. | 90 | $63,865 |
| Mallinckrodt Hospital Products Inc. | 81 | $42,273 |
| Mallinckrodt Enterprises LLC | 36 | $31,891 |
| Akebia Therapeutics Inc | 64 | $30,560 |
| AstraZeneca(2 entities) | 94 | $18,344 |
| Calliditas Therapeutics US Inc. | 39 | $13,947 |
| Johnson & Johnson | 5 | $3,570 |
| Aurinia Pharma U.S., Inc. | 26 | $608 |
| Travere Therapeutics, Inc. | 21 | $542 |
| Daiichi Sankyo Inc. | 13 | $322 |
| Boehringer Ingelheim | 13 | $308 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $182 |
| Apellis Pharmaceuticals, Inc. | 3 | $162 |
| OPKO Pharmaceuticals, LLC | 7 | $162 |
| GSK | 4 | $162 |
| AbbVie | 1 | $125 |
| La Jolla Pharmaceutical Company | 4 | $93 |
| Arbor Pharmaceuticals, Inc. | 5 | $84 |
| AMAG Pharmaceuticals, Inc. | 4 | $83 |
| Veloxis Pharmaceuticals, Inc. | 3 | $77 |
| Novartis | 3 | $75 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
| Chiesi USA, Inc. | 1 | $27 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$909,820 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 103 | $249,484 |
| KerendiaFinerenone | 262 | $245,213 |
| XphozahTenapanor Hcl | 81 | $229,955 |
| VeltassaPatiromer Calcium Sorbitex | 147 | $214,575 |
| FarxigaDapagliflozin Propanediol | 188 | $194,522 |
| LokelmaSodium Zirconium Cyclosilicate | 62 | $55,840 |
| AuryxiaFerric Citrate | 34 | $44,913 |
| DapagliflozinDapagliflozin Propanediol | 88 | $42,535 |
| InvokanaCanagliflozin | 36 | $35,491 |
| Sevelamer Carbonate | 147 | $24,908 |
| JardianceEmpagliflozin | 24 | $23,071 |
| Cinacalcet Hcl | 27 | $13,663 |
| Tacrolimus | 22 | $6,897 |
| ProsolParenteral Amino Acid 20% No.1 | 47 | $6,872 |
| Bumetanide | 120 | $5,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $18,344 | $250,363250 claims |
| Fresenius USA Marketing, Inc.Velphoro | $128,203 | $249,484103 claims |
| BayerKerendia | $144,863 | $245,213262 claims |
| Akebia Therapeutics IncAuryxia | $30,560 | $44,91334 claims |
| Johnson & JohnsonInvokana | $3,570 | $35,49136 claims |
| Boehringer IngelheimJardiance | $308 | $23,07124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Rancho Mirage
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.